HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.

AbstractOBJECTIVE:
The aim of this study was to compare the efficacy of the ultralow-dose estradiol vaginal ring with that of oral oxybutynin in the treatment of overactive bladder in postmenopausal women.
METHODS:
Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index.
RESULTS:
Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups.
CONCLUSIONS:
Ultralow-dose estradiol-releasing vaginal ring and oral oxybutynin seem to be similarly effective in decreasing the number of daily voids in postmenopausal women with overactive bladder.
AuthorsRebecca S Nelken, Begüm Z Ozel, Ava R Leegant, Juan C Felix, Daniel R Mishell Jr
JournalMenopause (New York, N.Y.) (Menopause) Vol. 18 Issue 9 Pg. 962-6 (Sep 2011) ISSN: 1530-0374 [Electronic] United States
PMID21532512 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Mandelic Acids
  • Muscarinic Antagonists
  • Estradiol
  • oxybutynin
Topics
  • Aged
  • Contraceptive Devices, Female
  • Estradiol (therapeutic use)
  • Female
  • Humans
  • Mandelic Acids (therapeutic use)
  • Middle Aged
  • Muscarinic Antagonists (therapeutic use)
  • Quality of Life
  • Treatment Outcome
  • Urinary Bladder, Overactive (drug therapy)
  • Urinary Incontinence (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: